Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Case Study · March 02, 2023

Excellent Response to Olaparib in a Patient With Metastatic HR+/HER2− Breast Cancer With BRIP1 Mutation

Annals of Oncology


Additional Info

Annals of Oncology
Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation
Ann. Oncol 2023 Mar 01;34(3)315-318, D Kwapisz, B Verret, C Garcia, F André

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading